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Introduction
Placing a coronary stent during angioplasty
minimizes reduces of acute vessel occlusion [1] and
restenosis [2]. Although permanent metallic stents
are effective in preventing recoil and late resteno-
sis after coronary angioplasty, they continue to have
limitations such as stent thrombosis and mismatch
of the stent to the vessel size. In-stent restenosis
is the major shortcoming of conventional (perma-
nent-implant) stent therapy. To mitigate the adver-
se effects of metallic stents, drug-eluting stents
have been developed. These also act as time-rele-
ased delivery mechanisms for antiproliferative
agents, thus further reducing restenosis.
There is no clear advantage, however, of ha-
ving stents remaining in the coronaries after they
are endothelized. On the contrary, there are docu-
mented disadvantages since incomplete healing can
induce a chronic inflammatory state increasing the
risk for thrombosis [3]. Permanently implanted
stents can also impair endothelial function [4], pre-
vent late favourable remodelling [5], and hamper
future imaging and reintervention.
Thus, the concept of bioabsorbable stents has
emerged as a viable alternative to permanent
stents. The idea behind the bioabsorbable stents is
to develop a device that provides scaffolding in the pe-
riprocedural phase and during short-term follow-up.
Bioabsorbable stents, once they are bioabsor-
bed, leave behind only the healed natural vessel,
allowing restoration of vasoreactivity with the po-
tential of vessel remodelling. Late stent thrombo-
sis is unlikely since the stent is gone, and prolon-
ged antiplatelet therapy is not necessary in this in-
stance. Bioabsorbable stents can also be suitable for
complex anatomy where stents impede on vessel
geometry and morphology and are prone to crushing
and fractures, such as is seen in saphenous femo-
ral and tibial arteries. Bioabsorbable implant stents
can be used as a delivery device for agents such as
drugs and genes, and will perhaps play a role in the
treatment of vulnerable plaque [6].
In addition, drug-eluting bioabsorbable stents
can deliver antiproliferative agents to reduce reste-
nosis and then dissolve over time, thereby elimi-
nating the disadvantages associated with permanent
stents.
In this paper we will briefly review the tech-
nology, preclinical, and initial clinical experimental
studies regarding bioabsorbable stents.
Bioabsorbable stent technology
A number of technologies suitable for bioabsor-
bable stents have been investigated so far. Magne-
sium and poly-L-lactic acid (PLLA) have been the
most widely used materials for construction of bio-
absorbable stents (Table 1).
Magnesium alloy bioabsorbable stents
The bioabsorbable magnesium stent is con-
structed from a magnesium alloy also containing
zirconium (< 5%), yttrium (< 5%), and rare earth
elements (< 5%). The struts disappear over time,
but their position can still be identified because of
the fact that the strut material is absorbed and the
space filled in by calcium apatite complex, accom-
panied by a phosphorous compound. These stents
are compatible with cardiac magnetic resonance
imaging and multi-slice computed tomography and
can be used as vehicles for possible drug and gene
delivery [7].
The magnesium alloy elements are well tole-
rated by the body, the degradation rate of the
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material can be adjusted, and the material is easily
deformable yet very rigid so it can support the blo-
od vessel.
Polymer bioabsorbable stents
The earliest polymeric bioabsorbable stent is
known as an “IGAKI-TAMAI” stent. This bioabsor-
bable stent is formed from biodegradable polymer
PLLA. The stent has the characteristics of being
dissolved into water and carbon dioxide and absor-
bed into vessel tissue within a few years after im-
plantation. It is also possible to use it for patients
who cannot receive stents because they are still
growing or due to metal allergies. Even though sten-
ted segments become narrow again, implanted PLLA
stents, which do not remain in the body permanen-
tly, will not interfere with other procedures such as
restenting. Furthermore, PLLA stents are more
useful for containing drugs compared to metal stents,
and thus have been intended as a platform for drug
eluting stents (Table 2).
A magnesium bioabsorbable stent was evalu-
ated in the PROGRESS-AMS study and had reste-
nosis and target lesion revascularization (TLR) ra-
tes similar to those seen for balloon-only angiopla-
sty [2, 9] (Table 3).
Another promising bioabsorbable drug-eluting
stent was developed by Abott Laboratories. Its bio-
absorbable everolimus-eluting coronary stent is made
of polylactic acid, said to be used in medical implants
such as dissolvable sutures. As with a metallic stent,
Table 3. Results of the PROGRESS AMS Study
[n = 63 patients, 71 stents, 63 de novo lesions at
8 centres] [9].
Outcome 4 months 1 year
TLR 25 (38%) 27 (45%)
Ischemia-driven TLR 15 (24%) 16 (27%)
MACE (cardiac 15 (24%) 16 (27%)
death, MI, TLR)
Outcome (mean) After 4
stenting  months
In-stent diameter 12.7% 48.4%
stenosis
In-stent acute gain [mm] 1.41
In-stent late loss [mm] 1.08
TLR — target lesion revascularization; MACE — major adverse
cardiac events; MI — myocardial infarction
Table 2. Initial and 6-month results of biodegra-
dable poly-L-lactic acid (Igaki-Tamai) coronary
stents in humans [n = 15 patients, 25 stents,
18 de novo and 1 restenotic lesion(s)] [8].
Before After 6 months
Outcome stenting stenting
TLR 10.5%
Minimal lumen 1.02 ± 0.36 2.59 ± 0.35 1.84 ± 0.66
diameter [mm]
Diameter 64 ± 11 12 ± 8 33 ± 18
stenosis (%)
Loss index* 0.48 ± 0.32
*Late loss + initial gain, TLR — target lesion revascularization
Table 1. Materials applied for development of biodegradable stents.
Material Stent Status References
Polymers
PLA Thermal ballon expandable, 4-year clinical data Tamai H et al., CCT 2004
ring (Igaki-Tamai)
PLA Ballon expandable, tubular Phase I Clinical trial Stack RS, TCT 2005
(Abbott Vascular, Inc.)  (Absorb)  Ormiston J, TCT 2006
Tyrosine- Ballon expandable Pre-clinical Kaluza G, TCT 2006
polycarbonate  (REVA Medical)
PAE-Salicylate Ballon expandable, tubular Pre-clinical Robinson KA, TCT 2006
Metalic
Magnesium Ballon expandable, Phase I Clinical Haublein B et al.,
tubular (Biotronik) Heart 2003; 89: 651–656
Iron Ballon expandable, tubular Pre-clinical Peuster M et al.,
Heart 2001; 86: 563–569
PLA — polylactide; PAE — poly(anhydride esters)
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Abbott’s bioabsorbable stent is designed to restore
blood flow by propping a clogged vessel open, and to
provide support until the blood vessel heals.
Data from ABSORB, the world’s first clinical
trial of Abott’s fully bioabsorbable drug eluting stent
for the treatment of coronary artery disease, de-
monstrated no stent thrombosis, no clinically
driven target lesion revascularizations (retreatment
of a diseased lesion), and a low (3.3%) rate of major
adverse cardiac events (MACE) in 30 patients out
to one year. Abbott’s prospective, non-randomized
ABSORB clinical trial is designed to evaluate the
overall safety and performance of a fully bioabsor-
bable everolimus eluting stent out to 5 years.
Abbott’s bioabsorbable everolimus eluting stent
has demonstrated excellent clinical safety out to one
year in patients with coronary artery disease.
The positive results from this clinical trial form
a strong basis for the development of additional bio-
absorbable stent platforms with the potential to eli-
minate some of the restrictions posed by non-
-absorbable metallic stents in areas such as vessel
imaging and vessel remodelling.
At 6 months, the overall MACE rate in the
ABSORB trial was 3.3% (1 patient, n = 30), and late
loss (a measure of reduction in vessel lumen diame-
ter after stenting) was 0.44 mm. At one year, the ove-
rall MACE rate in the ABSORB trial was consistent
with results at 6 months (1 patient, 3.3%, n = 30; 3.4%
adjusted for one patient who withdrew from follow-
up, known to be event free at 1 year, n = 29). MACE
was a composite measure of cardiac death, heart at-
tack, and re-treatment of a diseased lesion (ische-
mia-driven TLR) in the ABSORB trial. Abbott’s bio-
absorbable everolimus eluting stent also demonstra-
ted 100% procedural success and 94% device
success in the ABSORB trial (Table 4).
Conclusions
Drug eluting bioabsorbable stents have the
potential to revolutionize interventional cardiology.
The greatest challenge, however, remains the con-
trol of the bioabsorption rate.
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Table 4. Results of the ABSORB Study [n = 30
patients with single de novo lesion] [10].
Outcome 1 year
MACE (cardiac death, 3.3%
MI, ischemia-driven TLR,
1 NQWMI and no TLR)
Outcome (mean) After stenting 180 days
In-stent diameter 16% 27%
stenosis
In-stent acute gain [mm] 1.24
In-stent late loss [mm] 0.44
MACE — major adverse cardiac events; TLR — target lesion reva-
scularization; MI — myocardial infarction; NQWMI — non-Q-wave
myocardial infarction
